Trial intelligence / Profile preview

Blinatumomab and Olverembatinib in Ph+ ALL

NCT07178912Phase 2

Key facts

Status: Not yet recruiting
Start: Jan 2027
Primary completion: Sep 2031
Countries: 1
Sponsor: University of Texas MD Anderson Cancer Center
Modality: Antibody Conjugates, scFv Fragments, Small Molecules

Drugs: blinatumomabolverembatinib
Conditions: acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)

Overview

Phase 2, open-label, single-arm trial of blinatumomab and olverembatinib in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Complete Molecular Response and 1 more. Planned start Jan 2027; status: not yet recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Treatment with Blinatumomab (SC) + Olverembatinib (PO) Q5W
Patients will be receiving blinatumomab and olverembatinib.

Who it enrols

Adults with newly diagnosed or relapsed/refractory Ph+ and/or BCR::ABL1+ ALL or lymphoid accelerated/blast phase CML, with ECOG <= 2 and adequate organ function.

Endpoints

Primary

Safety and adverse events1 year
Complete Molecular Response
Overall Response Rate

Secondary

Event-Free Survival
Overall Survival
Minimal Residual Disease negativity

Beyond the preview

Go deeper on NCT07178912.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07178912.